JP2002537336A - ニトロソ化およびニトロシル化されたプロトンポンプ阻害剤、組成物および使用方法 - Google Patents

ニトロソ化およびニトロシル化されたプロトンポンプ阻害剤、組成物および使用方法

Info

Publication number
JP2002537336A
JP2002537336A JP2000600648A JP2000600648A JP2002537336A JP 2002537336 A JP2002537336 A JP 2002537336A JP 2000600648 A JP2000600648 A JP 2000600648A JP 2000600648 A JP2000600648 A JP 2000600648A JP 2002537336 A JP2002537336 A JP 2002537336A
Authority
JP
Japan
Prior art keywords
group
compound
nitric oxide
patient
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000600648A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002537336A5 (enExample
Inventor
エス． ガルベイ，ディビッド
レッツ，エル．，ゴードン
タム，サン，ウイリアム
ワン，ティアンシェン
ケー． リチャードソン，スチュワート
Original Assignee
ニトロメド インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ニトロメド インコーポレーテッド filed Critical ニトロメド インコーポレーテッド
Publication of JP2002537336A publication Critical patent/JP2002537336A/ja
Publication of JP2002537336A5 publication Critical patent/JP2002537336A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2000600648A 1999-02-26 2000-02-25 ニトロソ化およびニトロシル化されたプロトンポンプ阻害剤、組成物および使用方法 Pending JP2002537336A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12211199P 1999-02-26 1999-02-26
US60/122,111 1999-02-26
PCT/US2000/002524 WO2000050037A1 (en) 1999-02-26 2000-02-25 Nitrosated and nitrosylated proton pump inhibitors, compositions and methods of use

Publications (2)

Publication Number Publication Date
JP2002537336A true JP2002537336A (ja) 2002-11-05
JP2002537336A5 JP2002537336A5 (enExample) 2007-04-05

Family

ID=22400684

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000600648A Pending JP2002537336A (ja) 1999-02-26 2000-02-25 ニトロソ化およびニトロシル化されたプロトンポンプ阻害剤、組成物および使用方法

Country Status (5)

Country Link
EP (1) EP1154771A4 (enExample)
JP (1) JP2002537336A (enExample)
AU (2) AU781133B2 (enExample)
CA (1) CA2362930C (enExample)
WO (1) WO2000050037A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9243300B2 (en) 2011-01-07 2016-01-26 Snowden Kabushikikaisha Lactic acid bacterium for inhibiting production of gastric acid and gastrin

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0002476D0 (sv) 2000-06-30 2000-06-30 Astrazeneca Ab New compounds
WO2003043614A2 (en) * 2001-11-19 2003-05-30 Altana Pharma Ag Reversible proton pump inhibitors for the treatment of airway disorders
TW200403072A (en) * 2002-01-23 2004-03-01 Upjohn Co Combination therapy for the treatment of bacterial infections
WO2003075926A1 (en) * 2002-03-14 2003-09-18 Altana Pharma Ag Use of proton pump inhibitors for the treatment of airway disorders
WO2003082854A1 (en) * 2002-03-29 2003-10-09 Zeria Pharmaceutical Co., Ltd. 1-n-aminobenzimidazole derivatives
EP1497268A4 (en) * 2002-04-05 2006-01-18 Nitromed Inc NITROGEN OXIDE DISPENSER, COMPOSITIONS AND METHOD OF USE
AU2003254282A1 (en) * 2002-08-01 2004-02-23 Nitromed, Inc. Nitrosated proton pump inhibitors, compositions and methods of use
FR2845915B1 (fr) * 2002-10-21 2006-06-23 Negma Gild Utilisation du tenatoprazole pour le traitement du reflux gastro-oesophagien
FR2845917B1 (fr) * 2002-10-21 2006-07-07 Negma Gild Composition pharmaceutique associant le tenatoprazole et un anti-inflammatoire
EP1718303A4 (en) * 2004-02-10 2010-09-01 Santarus Inc COMBINATION OF INHIBITOR OF PROTON PUMP, BUFFER AND NON-STEROIDAL ANTI-INFLAMMATORY DRUG
TW200606163A (en) 2004-04-22 2006-02-16 Eisai Co Ltd Imidazopyridine compound
US20070015782A1 (en) 2005-04-15 2007-01-18 Eisai Co., Ltd. Benzimidazole compound
US9040564B2 (en) 2005-04-28 2015-05-26 Eisai R&D Management Co., Ltd. Stabilized composition
US20090018091A1 (en) 2005-08-02 2009-01-15 Nitromed, Inc. Nitric Oxide Enhancing Antimicrobial Compounds, Compositions and Methods of Use
JP7706169B2 (ja) * 2020-02-26 2025-07-11 上海科技大学 抗コロナウイルスにおけるジスルフィラムの使用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05117268A (ja) * 1991-10-22 1993-05-14 Yoshitomi Pharmaceut Ind Ltd ピリジン化合物
JPH10501253A (ja) * 1994-06-10 1998-02-03 ビイク グルデン ロンベルク ヒェーミッシェ ファブリーク ゲゼルシャフト ミット ベシュレンクテル ハフツング ヘリコバクター−細菌の撲滅のためのチオフィリジン
JPH10501254A (ja) * 1994-06-10 1998-02-03 ビイク グルデン ロンベルク ヒェーミッシェ ファブリーク ゲゼルシャフト ミット ベシュレンクテル ハフツング 置換アリールアルキルチオアルキルチオピリジン
WO1998028299A2 (en) * 1996-12-20 1998-07-02 Byk Gulden Lomberg Chemische Fabrik Gmbh Imidazopyridazines

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL105155A (en) * 1992-04-24 1999-05-09 Astra Ab Combination of a substance with gastric acid secretion inhibiting effect and an acid degradable antibiotic
EP0639644A1 (de) * 1993-08-16 1995-02-22 Ciba-Geigy Ag Neue Makrolide und ihre Verwendung
DE4420523A1 (de) * 1994-06-13 1995-12-14 Cassella Ag Verwendung von NO-freisetzenden Verbindungen zur Behandlung und Vorbeugung von systemischen Entzündungssyndromen
SE9500422D0 (sv) * 1995-02-06 1995-02-06 Astra Ab New oral pharmaceutical dosage forms
US5703073A (en) * 1995-04-19 1997-12-30 Nitromed, Inc. Compositions and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs
US6132768A (en) * 1995-07-05 2000-10-17 Byk Gulden Lomberg Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for reversible proton pump inhibitors
EP0941102A1 (en) * 1996-11-22 1999-09-15 The Procter & Gamble Company Compositions for the treatment of gastrointestinal disorders containing bismuth and nsaid
EP0983263A1 (en) * 1997-05-30 2000-03-08 Dr. Reddy's Research Foundation Novel benzimidazole derivatives as antiulcer agents, process for their preparation and pharmaceutical compositions containing them

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05117268A (ja) * 1991-10-22 1993-05-14 Yoshitomi Pharmaceut Ind Ltd ピリジン化合物
JPH10501253A (ja) * 1994-06-10 1998-02-03 ビイク グルデン ロンベルク ヒェーミッシェ ファブリーク ゲゼルシャフト ミット ベシュレンクテル ハフツング ヘリコバクター−細菌の撲滅のためのチオフィリジン
JPH10501254A (ja) * 1994-06-10 1998-02-03 ビイク グルデン ロンベルク ヒェーミッシェ ファブリーク ゲゼルシャフト ミット ベシュレンクテル ハフツング 置換アリールアルキルチオアルキルチオピリジン
WO1998028299A2 (en) * 1996-12-20 1998-07-02 Byk Gulden Lomberg Chemische Fabrik Gmbh Imidazopyridazines

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9243300B2 (en) 2011-01-07 2016-01-26 Snowden Kabushikikaisha Lactic acid bacterium for inhibiting production of gastric acid and gastrin

Also Published As

Publication number Publication date
CA2362930C (en) 2010-10-05
AU781133B2 (en) 2005-05-05
AU2005202553A1 (en) 2005-07-07
CA2362930A1 (en) 2000-08-31
EP1154771A1 (en) 2001-11-21
WO2000050037A1 (en) 2000-08-31
EP1154771A4 (en) 2005-04-20
AU3219600A (en) 2000-09-14

Similar Documents

Publication Publication Date Title
JP4634144B2 (ja) ニトロソ化プロトンポンプ阻害剤、組成物および使用方法
US6852739B1 (en) Methods using proton pump inhibitors and nitric oxide donors
US6693122B2 (en) Nitrosated and nitrosylated potassium channel activators, compositions and methods of use
CA2349575A1 (en) Nitrosated and nitrosylated h2 receptor antagonist compounds, compositions and methods of use
TWI388554B (zh) Ｎ-（胺基-雜芳基）-１ｈ-吲哚-２-甲醯胺衍生物，其製備及其治療用途
CA2362930C (en) Nitrosated and nitrosylated proton pump inhibitors, compositions and methods of use
JP2002523449A (ja) ニトロソ化およびニトロシル化されたα−アドレナリン受容体拮抗薬、組成物および使用方法
JP2002528495A (ja) ニトロソ化およびニトロシル化された非ステロイド抗炎症性化合物、組成物および使用方法
JP2006513202A (ja) 血管形成インヒビターとしてのピペリジニル−チアゾールカルボン酸誘導体
JP6107650B2 (ja) テトラヒドロカルボリン誘導体
WO1998019672A9 (en) Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
WO2010135976A1 (zh) 1-（取代苄基）-5-三氟甲基-2-（1h）吡啶酮化合物及其盐，其制备方法及其用途
TW200303860A (en) New compounds
ES2494765T3 (es) Compuestos y métodos para inhibir la interacción de proteínas BLC con compañeros de unión
JP4828142B2 (ja) 新規な融合ピラゾリル化合物
US5753667A (en) 1-oxo-2- (phenylsulphonylamino) pentylpiperidine derivatives, their preparation and their therapeutic application
JPH0639471B2 (ja) 抗潰瘍性（アルキルジチオ）キノリン誘導体
AU604398B2 (en) 8-(2-pyrimidyl sulfinyl) quinoline derivatives
AU2004202027B2 (en) Nitrosated and nitrosylated H2 receptor antagonist compounds, compositions and methods of use
WO2021072487A1 (en) Sulfonamide compounds and the use thereof in the treatment of cancer
AU2004201585B2 (en) Nitrosated and nitrosylated alpha-adrenergic receptor antagonists, compositions and methods of use
WO2001010844A1 (fr) DERIVES D'ACIDE φ-AMINO-α-HYDROXYCARBOXYLIQUE POSSEDANT UN ANTAGONISME αvβ3 D'INTEGRINE
CZ2001457A3 (cs) Proléčiva inhibitorů protonové pumpy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070213

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070213

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20090623

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20090623

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20090803

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100407

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100702

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100927